Showcase the Broad Therapeutic Potential of HCB101 in Tumor Immunotherapy
-
As the only innovative drug company from Taiwan invited to this year’s CBA Annual Conference, HanchorBio took the international stage to present its AI-assisted Structural Engineering on SIRP-alfa fusion biologic for enhancing Safety and Efficacy, marking an important milestone for Taiwan’s biotech industry.
-
This recognition not only strengthens Taiwan’s position in global AI-assisted drug development, but also opens new opportunities for cross-border licensing and collaboration.
Registration: Eventbrite
October 2, 2025 – HanchorBio today announced that the company has been invited to participate in the 27th Annual Conference of the Chinese Bioscience Association (CBA), to be held in Foster City, California, where it will present the broad therapeutic potential of its innovative drug candidate HCB101 in tumor immunotherapy.
Dr. Scott Liu, Founder, Chairman, and CEO of HanchorBio Inc., as a winner of the 2022 CABS K. Fong Award in Life Sciences for the outstanding contribution to the development of multiple biologic products from research to launch from the Chinese-American Biopharmaceutical Society (CABS) and will deliver a featured presentation titled “Engineering of SIRP-alpha through AI-assisted structural modeling for enhanced safety and efficacy” on October 4, 2025, from 15:35 to 16:00 PDT. The presentation will highlight how AI-assisted structural modeling can be applied to the engineering of SIRP-alpha, aiming to improve drug safety and efficacy, and will showcase the promise of HCB101 as a next-generation immunotherapy for cancer.
Event Information
- Conference Name: CBA Chinese Bioscience Association 27th Annual Conference
- Theme: Charting new territories: advancing ADCs and Next-generation neurodegenerative therapies
- Date & Time: October 4, 2025, 15:35–16:00 PDT
- Location: Crowne Plaza Foster City-San Mateo (1221 Chess Drive, Foster City, CA 94404, United States)
- Presentation Title: Engineering of SIRP-alpha through AI-assisted structural modeling for enhanced safety and efficacy
- Speaker: Dr. Scott Liu, Chairman of HanchorBio
In recent years, the global biopharmaceutical industry has experienced unprecedented growth. With advances in science and the rising demand for healthcare, research and applications in the biopharmaceutical field have made remarkable progress. Breakthroughs in drug discovery, gene therapy, and cell therapy continue to emerge, injecting new momentum into the industry. Meanwhile, the market size of biopharma continues to expand, drawing increasing investment and global attention.
About the CBA 27th Annual Conference
The CBA Annual Conference is a premier event for the global Chinese biopharmaceutical community, dedicated to fostering academic exchange, innovation, and international collaboration. This year’s conference, themed “Charting new territories: advancing ADCs and Next-generation neurodegenerative therapies”, will focus on key frontier topics, including:
- Global regulatory updates
- Innovations in technology and AI applications
- Breakthroughs in advanced therapeutics
- Strategies for drug discovery and development
- Emerging market opportunities and global expansion
About HanchorBio
HanchorBio is dedicated to developing innovative fusion protein biotherapeutics that harness the immune system to fight cancer. At the core of its innovation is the proprietary FBDBTM platform, which enables the precise design of multi-target biologics within a single molecule, delivering both enhanced efficacy and improved safety. HanchorBio is committed to advancing next-generation immunotherapies, including HCB101, with the goal of addressing unmet medical needs and bringing transformative treatment options to cancer patients worldwide.
Registration: Eventbrite
